Skip to content
Popular Searches
  • # Cancer
  • # Alzheimer's
  • # FDA
  • # DNA
  • # COVID19
  • # CRISPR
  • linkedin
  • facebook
  • instagram
  • twitter
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Amgen Released Phase 3 MINT Trial Data Evaluating the Efficacy and Safety of UPLIZNA® (inebilizumab-cdon)

14 March 2025

Researchers developed AI-designed DNA switches which can flip genes

24 October 2024

Gliead Releases the Results of Phase 3 ASCENT-04/KEYNOTE-D19 Trials Shows Positive Effect for Combinational Use of Trodelvy® Plus Keytruda®

22 April 2025

Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts

4 May 2025

Reprogramming of T cells to fight against ageing – Research

31 January 2024

Classifying the natural history of asymptomatic malaria – Research

7 January 2024

Conjunctivitis – Cause, Diagnosis, and Treatment

22 August 2023

Pfizer With Arvinas Announced Positive Results of Phase 3 VERITAC-2 Clinical Trial for Advanced or Metastatic Breast Cancer

11 March 2025

Reduced risks of common diseases through the inherited predisposition for higher muscle strength

16 April 2024

New studies investigate potential treatments for cancer and other illnesses

6 December 2024

New regenerative medicine research could revolutionize the treatment of type 1 diabetes and open the door to treating autoimmune diseases and cancer.

26 November 2024

Researchers developed gel-mediated cancer drug delivery for solid tumors

14 November 2023

INEBILIZUMAB-CDON

U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder
Business Healthcare & Pharmaceuticals News Regulatory Approval

U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder

Athulya B S 6 April 2025

IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.

Areas Covered

  • Anti-obesity Drugs
  • Applications of Biotechnology
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Staining
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Amgen Hiring Senior Data Engineer in Hyderabad, India – May 2025
  • Novo Nordisk Hiring Senior Regulatory Affairs Specialist in Seoul, South Korea – May 2025
  • Pfizer Hiring an IT Senior Associate in Chennai, India – April, 2025
  • IQVIA Hiring Clinical Data Specialist in Cochin, India – April 2025
  • Amgen Hiring CRM Engineer (Veeva/Salesforce) in Hyderabad, India – April, 2025
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy